{
    "eid": "2-s2.0-85062688767",
    "title": "Pulsed-dye laser as an adjuvant treatment for papulopustular eruptions from epidermal growth factor receptor inhibitors, a randomized blinded split-faced controlled trial",
    "cover-date": "2019-09-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Surgery",
            "@code": "2746",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Dermatology",
            "@code": "2708",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "acne",
        "EGFRi",
        "epidermal growth factor receptor inhibitors",
        "papulopustular",
        "pride",
        "pulsed-dye laser",
        "treatment"
    ],
    "authors": [
        "Pawinee Rerknimitr",
        "Yada Suphankong",
        "Ratchathorn Panchaprateep",
        "Stephen J. Kerr",
        "Pravit Asawanonda"
    ],
    "citedby-count": 1,
    "ref-count": 22,
    "ref-list": [
        "Targeting the EGFR pathway for cancer therapy",
        "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma",
        "Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study",
        "Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial",
        "Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer",
        "Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities",
        "Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors",
        "A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis",
        "Advances in the management of cutaneous toxicities of targeted therapies",
        "Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane",
        "Erlotinib induced target-like purpura",
        "Pulsed-dye laser as an adjuvant treatment for discoid lupus erythematosus: A randomized, controlled trial",
        "A comparative split-Face study using different mild purpuric and subpurpuric fluence level of 595-nm pulsed-Dye laser for treatment of moderate to severe acne vulgaris",
        "The efficacy of pulsed dye laser treatment for inflammatory skin diseases: A systematic review",
        "Epidermal EGFR controls cutaneous host defense and prevents inflammation",
        "Investigation of the mechanism of action of nonablative pulsed-dye laser therapy in photorejuvenation and inflammatory acne vulgaris",
        "Intense pulsed light vs. pulsed-dye laser in the treatment of facial acne: A randomized split-face trial",
        "Management of egfr tki-induced dermatologic adverse events",
        "Expert Consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK",
        "Pan canadian rash trial: A randomized phase III trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth factor receptor-Tyrosine kinase inhibitor-Induced skin toxicities in patients with metastatic lung cancer",
        "Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management",
        "Acne erythema improvement by long-pulsed 595-nm pulsed-dye laser treatment: A pilot study"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60028190",
        "affilname": "Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
        "affiliation-country": "Thailand"
    },
    "funding": [
        "Department of Medicine, Faculty of Medicine",
        "Division of Medical Oncology",
        "Chulalongkorn University"
    ]
}